[406] Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegan EW, A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994; 43: 1203-10.
[407] Gomi-Berthold J, Berthold HK, Weber AA, Seul C, Vetter H, Sachinidis A. Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth. Exp Clin Endocrinol Diabetes 2001; 109: 203-9.
[408] Salzman A, Patel J. Rosiglitazone is not associated with hepatotoxicity [abstract], Diabetes 1999; 48 (suppl 1): A95.
[409] Ferman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Int Med 2000; 132: 118-21.
[410] Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient recieving rosiglitazone: a case report. Ann Intern Med 2000; 132: 121-4.
[411] Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure [letter]. Ann Intern Med 2000; 132: 164.
[412] Aronof SH, Rosenblatt S, Braithwaite S, Egan SW, Mathisen AL, Schneider RL, the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000; 23: 1605-11.
[413] Gale EAM. Lessons from the glitazones: a story of drug development. Lancet 2001; 357: 1870-5.
[414] Fonseca V, Rosenstock J, Patwardhau R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus–a randomized controlled trial. JAMA 2000; 283: 1695-702.
[415] Wolffenbuttel BHR, Gomis R, Squatrito S, Jones MP, Patwardhan RN. Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000; 17: 40-7.
[416] Buse JB. Pioglitazone in the treatment of type 2 diabetes mellitus: US clinical experience. Exp Clin Endocrinol Diabetes 2000; 108 (suppl 2): S250-5.
[417] Ghazzi MN, Perez JE, Antonui TK, Driscoll JH, Huang SM, Faja BW, the Troglitazone Study Group, Whitcomb RW. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46: 433-9.
[418] Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet 1994; 343: 95-100.
[419] Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 1997; 278: 1663-9.
[420] Chow CC, Tsang LWW, Sörensen JP, Cookram CS. Comparison of insulin with or without combination of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995; 18: 307-14.
[421] Pugh JA, Wagner ML, Sawyer J, Ramirez G, Turley M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients: a metaanalysis. Diabetes Care 1992; 15: 953-9.
[422] Bruns W, Melchert J, Fischer S, Köhler C, Julius U, Gudat U, Pfützner A, Frank M, Hanefeld M. Präprandiale komplementäre Insulintherapie bei übergewichtigen Typ 2 Diabetikern mil Normalinsulin Oder schnell wirkenden Insulinanalogen (Lispro-Insulin)? Diabel Stoffw 2000; 9: 219-25.
[423] Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppälö P, Tulokas T, Viikari J, Karjalainen J, Taskinen M-R. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-33.
[424] Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Johnson Nagel N, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS, VA CSDM Group. Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Diabetes Care 1995; 18: 1113-23.
[425] Bloomgarden ZT. Non-insulin-dependent diabetes mellitus. Diabetes Care 1995; 18: 1215-9.
[426] Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10 year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000; 48: 201-10.
[427] Bailey S, Mezitis NHE. Combination therapy with insulin and sulfonylureas for type II diabetes. Diabetes Care 1990; 13: 687-95.
[428] Lebowitz HE, Pasmantier R. Combination insulin-sulfonylurea therapy. Diabetes Care 1990; 13: 667-75.
[429] Pyörälä K, Pedersen TR, Kjekshns J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-20.
[430] Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E, for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the cholesterol and recurrent event (CARE) trial. Circulation 1998; 98: 2513-9.
[431] Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999; 353: 617-22.
[432] Panzram G. Mortalität und Lebenserwartung des insulinabhängigen Typ 2 Diabetes. Diabetes Dialog 1992; 1: 1-4.
[433] Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JC, Roep BO: Development of type 1 diabetes despite severe hereditary β-cell deficiency. New Engl J Med 345: 1036-1040(2001)
[434] Klein R, Klein BEK, Moss SE, Cruickshank KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIV, Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112: 1217-28.
2 Structure and Function of the Nervous System
N. E. Cameron and C. J. Mathias
The Somatic Nervous System
N. E. Cameron
The somatic nervous system is subdivided into motor and sensory components. The motor division is concerned with control of skeletal muscle contraction, and hence of voluntary movement and of posture and reflexes. The somatosensory division is a collection of receptors, tracts, and nuclei that convey the sensations of light touch, vibration, temperature, and pain (nociception) to the consciousness. It also conveys information about movements and position of the body (proprioception and kinesthesia). Somatosensory receptors are found in the skin, muscles, joints, and viscera. In addition to providing sensation, the somatosensory division has a critical role in motor control, through feedback about muscle length and tension, joint position, velocity of muscle and limb movement, and contact with external surfaces. The basic structure and function of the somatic nervous system has been described in numerous physiology, neurology, and neuroscience texts: the reader is referred to two recent books for further information [1,2]. Diabetes affects both the peripheral and the central nervous system (for discussion of the latter see Chapter 5, page 205-208), although most clinical and scientific interest has focused on the periphery because of the devastating effect on nerve fiber integrity. This section provides an overview of the substrate of the somatic nervous system, with a greater emphasis on peripheral than on central structures.
Fig. 2.1 General organization